Koya Medical announces positive interim results from randomized controlled study of Dayspring active compression treatment for lymphedema and venous disease.

Procyrion is proud to be recognized as a Fierce15 Medtech company this year! Check out the interview with our CEO Eric Fain to learn more about our innovative Aortix™ technology and the potential it has to change the way patients with acute decompensated heart failure and cardiorenal syndrome are treated.

Thomas Maldonado brings two decades of vascular care experience, including his tenure at NYU, to Koya Medical’s advisory board as the new Chief Medical Officer.

Mindera Health, a leader in precision medicine for dermatological conditions, today announced their participation in MultiPlan’s national PPO networks. Effective immediately, health plan members who access MultiPlan’s PHCS and MultiPlan Networks have access to Mindera’s Vista, CA-based laboratory that performs its proprietary test Mind.Px™. “Our vision is to realize the clinical and economic benefits of

Mayumana Healthcare is pleased to announce its exclusive distribution rights in the Netherlands for the Cerene® Cryotherapy Device.

Strategic collaboration will empower Podimetrics to help prevent 70%+ of amputations and reduce hospital admissions for high-risk diabetes patients.

Koya CEO, Andy Doraiswamy, PhD, will share updates on the company’s progress at the Piper Sandler 36th Annual Healthcare Conference

Podimetrics ranks No. 128 on Deloitte’s Technology Fast 500, marking significant growth in technology sectors across North America.

Explore the challenges and solutions for managing diabetes distress, particularly among dual-eligible populations. Learn how proactive mental health support and integrated case management can enhance patient outcomes. Discover the role of healthcare providers in delivering comprehensive care and reducing diabetes-related complications.

Eirion to Present Update on Its Neuromodulator Product Candidates at The Medical Aesthetic Injectable Summit 2024October 1, 2024 – Woburn, MA – Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, announced today that successful results had been achieved in its Phase 1 – 2 clinical trial for the treatment of moderate to severe glabellar wrinkles using its next generation, ready-to-use liquid injectable neuromodulator AI-

Lucas is an Industry veteran who brings expertise in commercialization, operations, business development, and finance to Procyrion as it continues to focus on its DRAIN-HF pivotal IDE trial and begins preparation for US commercialization of its Aortix percutaneous mechanical circulatory support (pMCS) technology.

WOBURN, Mass., July 1, 2024 /PRNewswire/ — Eirion Therapeutics Inc. announced today that the first participant has been enrolled in a Phase 1 clinical trial to evaluate the safety of the patented topical pharmaceutical ET-02 for the treatment of androgenic alopecia (age-related hair loss). This double-blind, placebo-controlled study is designed to determine the safety of ET-02 for once daily treatment over 28 days. The study is expected to recruit approximately 24 subjects at three investigatio

The PREVENT study is the pivotal clinical trial of the VentFree® Respiratory Muscle Stimulator and will support FDA regulatory clearance of VentFree CRESTWOOD, KY 9 April 2024 – Liberate Medical is proud to announce the successful commencement of patient enrollment in the PREVENT trial, a pivot